TITLE: Gut microbiome diversity is an independent predictor of survival in cervical cancer
 patients receiving chemoradiation

3

#### 4 Authors and Affiliations

5 Travis T. Sims, MD, MPH<sub>1+</sub>, Molly B. El Alam, MPH<sub>2+</sub>, Tatiana V. Karpinets, PhD<sub>3</sub>, Stephanie

6 Dorta-Estremera, PhD4, Venkatesh L. Hegde, PhD4, Sita Nookala, PhD4, Kyoko Yoshida-Court,

7 PhD2, Xiaogang Wu, PhD3, Greyson W. G. Biegert, BS2, Andrea Y. Delgado Medrano, BS2,

8 Travis Solley, BS2, Mustapha Ahmed-Kaddar, BS2, Bhavana V. Chapman, MD2, K. Jagannadha

9 Sastry, PhD4, Melissa P. Mezzari, PhD5, Joseph F. Petrosino, PhD5, Lilie L. Lin, MD2, Lois

10 Ramondetta, MD1, Anuja Jhingran, MD2, Kathleen M. Schmeler, MD1, Nadim J Ajami, PhD3,

11 Jennifer Wargo, MD, MMSc6, Lauren E. Colbert, MD, MSCR2\*, Ann H. Klopp, MD, PhD2\*

12 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2Department of Radiation Oncology, The University 13 14 of Texas MD Anderson Cancer Center, Houston, TX, USA. 3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4Department of 15 16 Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center and the UTHealth Graduate School of Biomedical Sciences at Houston, Houston, TX, 17 5Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and 18 Microbiome Research, Baylor College of Medicine, Houston, TX, USA. 6Department of Surgical 19 Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 20

21 + Authors Contributed Equally

22 \* Shared corresponding authorship

24	Correspondence: L.E. Colbert or A.H. Klopp, Department of Radiation Oncology, Unit
25	1422, The University of Texas MD Anderson Cancer Center, 1515 Holcombe
26	Boulevard, Houston, TX 77030, USA. Telephone: 832-652-6033 (L.E.C.), 713-563-2444
27	(A.H.K); fax: 713-745-2398; e-mail: lcolbert@mdanderson.org,
28	aklopp@mdanderson.org.
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

#### 47 ABSTRACT

Diversity of the gut microbiome is associated with higher response rates for cancer patients 48 receiving immunotherapy but has not been investigated in patients receiving radiation therapy. 49 Additionally, current studies investigating the gut microbiome and outcomes in cancer patients 50 may not adjusted for established risk factors. Here, we sought to determine if diversity and 51 52 composition of the gut microbiome was independently associated with survival in cervical cancer patients receiving chemoradiation. Our study demonstrates that the diversity of gut microbiota is 53 associated with a favorable response to chemoradiation. Additionally, compositional variation 54 55 among patients correlated with short term and long-term survival. Short term survivor fecal samples were significantly enriched in Porphyromonas, Porphyromonadaceae, and Dialister, 56 whereas long term survivor samples were significantly enriched in Escherichia Shigella, 57 Enterobacteriaceae, and Enterobacteriales. Moreover, analysis of immune cells from cervical 58 tumor brush samples by flow cytometry revealed that patients with a high microbiome diversity 59 60 had increased tumor infiltration of CD4+ lymphocytes as well as activated subsets of CD4 cells expressing ki67+ and CD69+ over the course of radiation therapy. The modulation of gut 61 microbiota before chemoradiation might provide an alternative way to enhance treatment efficacy 62 63 and improve treatment outcomes in cervical cancer patients.

64 Key words: gynecologic cancer, cervical cancer, HPV-associated cancers, microbiome,65 chemoradiation

- 66
- 67
- 68
- 69

#### 70 **MAIN**

Cervical cancer continues to be one of the leading causes of cancer-associated mortality globally1.
More than 500,000 new cases of invasive cervical cancer will be diagnosed worldwide in 2020,
resulting in over 300,000 deaths2. Multimodality therapy consisting of definitive chemoradiation
(CRT) comprising external-beam radiotherapy (EBRT) followed by intracavitary brachytherapy
with concurrent systemic chemotherapy continues to be the standard of care in clinical practice for
locally advanced disease3.

The fecal or gut microbiome, a diverse community of bacteria, archaea, fungi, protozoa, 77 and viruses, is thought to influence host immunity by modulating multiple immunologic pathways, 78 thus impacting health and disease4-6. The diversity of the gut microbiome is defined as the number 79 and relative abundance distribution of these distinct types of microorganisms colonizing within 80 the gut7. Studies have suggested that dysbiosis of the gut microbiome confers a predisposition to 81 certain malignancies and influences the body's response to a variety of cancer therapies, including 82 83 chemotherapy, radiotherapy, and immunotherapy<sub>6,8-11</sub>. For example, melanoma patients are more likely to have a favorable response to immune checkpoint blockade and exhibit improved systemic 84 and antitumor immunity if they have a more diverse intestinal microbiome11. 85

Radiotherapy promotes the activation of T cells directed against tumor antigens<sub>12-15</sub>. In combination with immunotherapy, radiotherapy can maximize the antitumor immune response and promote durable disease control<sub>16,17</sub>. We theorize that the gut microbiota may modulate radioresponse through immunologic mechanisms<sub>14,18</sub>. Studies investigating the gut microbiome and outcomes in cancer patients often do not adjust for confounding patient and tumor characteristics. To assess this, we sought to identify independent gut microbial risk factors in cervical cancer (CC) patients receiving chemoradiation (CRT) and to evaluate their impact on 93 survival. We hypothesize that gut microbial differences may affect clinical outcomes in patients94 with cervical cancer

95

#### 96 **RESULTS**

#### 97 *Patient Characteristics*

98 A total of 55 patients with a mean age of 47 years (range, 29-72 years) volunteered to participate in this study. The patients received standard treatment for cervical cancer with 5 weeks 99 of EBRT and weekly cisplatin. After completion of EBRT, patients received brachytherapy. For 100 evaluation of treatment response, patients underwent magnetic resonance imaging (MRI) at 101 baseline and week 5 and positron emission tomography (PET)/computed tomography (CT) 3 102 months after treatment completion (Fig. 1a). Most patients had stage IIB disease (51%) and 103 squamous histology (78%). Their clinicopathologic data are summarized in Supplementary Table 104 1. We staged cervical cancer using the 2014 International Federation of Gynecology and Obstetrics 105 106 staging system. The median cervical tumor size according to MRI was 5.4 cm (range, 1.2-11.5 cm). Thirty patients (55%) had lymph node involvement according to imaging studies. We first 107 analyzed the bacterial 16S rDNA (16Sv4) fecal microbiota at baseline with respect to disease 108 109 histology, grade, and stage. We found that the baseline  $\alpha$ -diversity (within tumor samples) and  $\beta$ diversity (between samples) of the fecal microbiome in the cervical cancer patients did not differ 110 111 according to histology, grade, or stage (P > 0.05) (Supplementary Fig. 1a-d).

Univariate and multivariate analysis of factors affecting recurrence free survival (RFS) and
overall survival (OS)

114 In the univariate Cox proportional hazard regression model predicting RFS, 3 covariates 115 showed P  $\leq$  0.2. As shown in Table 1, univariate analysis identified older age (Hazard Ratio (HR)

of 0.93 (95% CI = 0.87-0.98, P = 0.0096)), Shannon diversity index (SDI) (HR of 0.51 (95% CI = 116 0.23-1.1, P = 0.087)) and body mass index (BMI) (HR of 0.92 (95% CI = 0.84-1, P = 0.096)) as 117 risk factors for RFS. Multivariate survival analyses identified BMI and SDI as independent 118 prognostic factors for RFS with a HR of 0.87 (95% CI = 0.77-0.98, P = 0.02) and 0.36 (95% CI = 119 0.15-0.84, P = 0.018) respectively. As shown in Table 2, univariate analysis identified SDI (HR of 120 121 0.34 (95% CI = 0.1-1.1, P = 0.08) and BMI (HR of 0.83 (95% CI = 0.69-1, P = 0.055)) as risk factors for OS. For OS, multivariate survival analyses again identified BMI and SDI as 122 independent prognostic factors with a HR of 0.78 (95% CI = 0.623 - 0.97, P = 0.025) and 0.19 (95% 123 CI = 0.043-0.83, P = 0.028) respectively. 124

#### 125 Baseline Gut Microbiota Diversity is Associated with Favorable Responses

During the median follow-up period of 24.5 months, 7 patients died; all patients (12.7% of 126 the total study population) died of disease (DOD). Figure 1 shows the Kaplan-Meier curves for 127 RFS and OS. Given our univariate and multivariate analyses performed by Cox proportional 128 129 hazard model identified SDI as an independent predictor for RFS and OS, we first tested the relationship between gut diversity and RFS and OS in our cohort by stratifying patients based on 130 high and low SDI. We stratified the patients by SDI as high-diversity versus low-diversity groups 131 132 based on the cutoff value of SDI (2.69) calculated by receiver operating characteristic curve (ROC). We demonstrate that patients with high fecal alpha diversity at baseline showed a trend 133 134 toward prolonged RFS and OS when compared to those with low diversity (P = 0.16 and 0.094, 135 respectively) (Fig. 1a,b). Next, because our univariate and multivariate analyses performed by Cox 136 proportional hazard model also identified BMI as an independent predictor for RFS and OS, we tested the relationship between diversity and RFS and OS in our cohort by stratifying patients 137 138 based on high and low Shannon diversity metric and normal or high BMI. As shown in Figure

139 1d,e, when BMI and gut diversity are stratified for at baseline, patients with normal BMI and 140 higher SDI had a longer median RFS duration (P = 0.0027) (Fig. 1d). OS (Fig. 1e) was longer for 141 patients with normal BMI and higher gut diversity (P = 0.2).

#### 142 Compositional Difference in Gut Microbiome in Response to chemoradiation

To further investigate whether the composition of gut microbiome was associated with 143 144 response to CRT, we used Linear discriminant analysis (LDA) Effect Size analysis to identify bacterial genera that were differentially enriched in short term and long term cervical cancer 145 patients (P < 0.05; LDA score > 3.5). In all patients, multiple taxa differed significantly at baseline 146 between short and long term survivors. Specifically, short term survivor fecal samples were 147 significantly enriched in *porphyromonas*, *porphyromonadaceae*, and dialister, whereas long term 148 survivor samples were significantly enriched in Escherichia Shigella, Enterobacteriaceae, and 149 *Enterobacteriales* (P < 0.05; LDA score > 3.5, Fig. 2a,b). Our univariate analyses performed by 150 Cox proportional hazard model identified Pasteurellales, Haemophilus and Veillonella as 151 152 independent predictors for RFS and OS. We tested the relationship between these taxa and RFS and OS in our cohort by stratifying patients based on their relative abundance at baseline 153 (Supplemental Fig. 2). We demonstrate that patients with high relative abundance of Veillonella 154 155 at baseline showed a trend toward prolonged RFS and OS when compared to those with a low relative abundance at baseline (P = 0.08 and P = 0.054, respectively). 156

#### 157 Association between Gut Microbiota Profile and Immune Signatures

Because the gut microbiota is thought to influence disease progression partially through modulating local immune response, we analyzed the cervical tumors in our cohort of patients via flow cytometry on tumor brushings performed before week 1, week 3 and week 5 of radiation therapy. To identify features associated with high gut diversity, Spearman correlation analysis was 162 conducted between immune signatures at each time point. High SDI was positively correlated with
163 tumor infiltration of CD4 T cells at week 3, and CD4ki67+ T-cells at week 5, (Table 3 and Fig.
164 3a-d). These results suggest that patients with high gut diversity develop increased infiltration of
165 activated CD4+ T-cell subsets.

166

#### 167 **DISCUSSION**

The aim of this study was to identify independent gut microbial risk factors in cervical cancer 168 patients receiving chemoradiation and to evaluate their impact on survival. We found BMI and gut 169 diversity to be independent risk factors for RFS and OS in cervical cancer patients undergoing 170 chemoradiation. Higher alpha gut diversity at baseline correlated with an improved RFS and OS. 171 Our results indicate that overweight or obesity is a favorable prognostic factor independent of gut 172 diversity. Additionally, our results demonstrate that patients with better clinical survival exhibit 173 higher diversity as well as a distinct gut microbiome composition. Lastly, the association between 174 175 gut diversity and local immune signatures highlights helper CD4+ T cells as potential mediators of antitumor immunity upon CRT treatment. Taken together, our results imply that the diversity 176 of gut microbiota might be a shared benefit factor in those who respond well to CRT treatment. 177

It is now generally accepted that the gut microbiome modulates immune responses, antitumor immunity, and clinical outcomes in a variety of malignancies9,11,19. The gut microbiome is thought to affect both innate and adaptive immune responses. Specifically how the gut microbiome exerts its influence continues to be explored, but this explanation may have important implications if specific taxa are found to change host response to treatment via immunomodulation6. In our study, T helper cell profiles at baseline correlate with gut diversity. These results confer that T cells and response to CRT are likely affected by the gut microbiota

independent of other factors such as BMI. Using multi-color flow cytometry we performed 185 correlation analysis on individual immune signatures and microbiome diversity. The frequency of 186 187 helper CD4+ T cells were chiefly identified. Cervical cancer is considered to be an immunogenic tumor because its origin is dependent on a persistent infection with human papillomavirus (HPV), 188 most often HPV16 or HPV1820. Previous studies have reported that the number and functional 189 190 orientation of tumor-infiltrating CD4+ and CD8+ T cells and the presence of M1 type macrophages strongly correlates with survival in patients with cervical cancer after chemoradiation<sub>20,21</sub>. T cells 191 are capable of rapid antigen-specific responses and play critical roles in immune recall responses. 192 In addition to the percentage of CD4+ T cell subsets, the increase in CD4 Ki67, CD4 CD69, and 193 CD4 PD1 in patients with high microbiota diversity implies that the gut microbiome also 194 modulates the proliferation of certain immune cell populations. Recent studies have already 195 reported that chemoradiotherapy for cervical cancer induces unfavorable immune changes 196 reflected by a decreased number of circulating lymphocytes, both CD4+ and CD8+ T cells, and an 197 198 increased percentage in myeloid-cell populations, including myeloid-derived suppressor cells and monocytes<sub>20</sub>. Our study suggest that CD4+ T cells infiltrating the tumor microenvironment support 199 and encourage the activity of other immune cells by releasing T cell cytokines. 200

We found gut diversity to be associated with a favorable response to CRT against cervical cancer. Considering the correlation between gut diversity and local helper T cells being reshaped upon CRT treatment, we propose that patients harboring a more diverse gut microbiota at baseline may benefit from CRT to a greater extent. This might be mediated by the reprogramming of local antitumor immune responses. The significance of our study lies in that the modulation of gut microbiota before treatment might provide an alternative way to enhance the efficacy of CRT, specifically in advanced staged disease in which systemic failure of current therapies represents a 208 major challenge. Our results suggest that changes in the gut microenvironment contribute 209 substantially to treatment success or failure, particularly in so-called immunogenic tumors like 210 cervical cancer.

Our own group has previously characterized the gut microbiome of cervical cancer patients 211 compared to healthy female controls, and have reported on differences in the relative abundance 212 213 of specific taxa22. Our new findings support the hypothesis that organisms inhabiting the gut microbiome may be manipulated to improve cancer treatment response. Knowing specific gut 214 microbial organisms that inhabit and undergo changes in patients with cervical cancer during CRT 215 provides further insight into mechanisms that may modulate immune response and potentiate 216 treatment outcomes in cancer patients. Researchers have already studied the treatment-enhancing 217 utility of the gut microbiota in multiple areas of medicine10,23. Additionally, there is emerging data 218 describing the influence of the gut microbiome as it pertains to radiotherapy<sub>24</sub>. Given that radiation 219 can change the composition of the gut microbiome by altering the relative abundance of different 220 221 taxa, we have to postulate whether radioresistant taxa ultimately alter the effectiveness of radiotherapy for cervical cancer6,25,26. The results of our study illustrate the potential of 222 intentionally modifying the gut microbiota to accumulate CRT-tolerant species as an interventional 223 224 strategy to enhance response of cervical cancer to CRT. Furthermore, determining whether changes in the human gut microbiome during CRT affect patients' risk of treatment-related toxic 225 226 effects may be an area that deserves further investigation.

The "obesity paradox", which suggest a positive association between increasing BMI as it pertains to a specific disease, was firstly reported in heart failure<sup>27</sup>, but has since been described in a variety of disease processes, including other gynecologic cancers<sup>28–30</sup>. Theories centered around the "obesity paradox" suggest that patients with a high BMI may be better able to withstand

cancer-induced consumption and stress compared with patients with a low BMI31. In uterine cancer 231 it has been reported that the risk of recurrence differed significantly by BMI32. Specifically, a 232 233 greater proportion of obese women met criteria for having a low risk of recurrence, while thin women tended to have a high-intermediate risk or recurrence. Many studies have investigated the 234 impact of BMI on cervical cancer, but the association between weight and cervical cancer remains 235 236 ambigous<sub>33</sub>. HPV is considered to be responsible for 99.7% of all cervical cancers<sub>34</sub>, however, it has been suggested that obesity may further increase this risk35–37. Other reports however do not 237 report an association<sub>38,39</sub>. For example, a review by Lane *et al.* finally refuted the relationship 238 between cervical cancer and obesity ultimately siting a lack of evidence<sup>40</sup>. The inconsistent 239 conclusions among studies investigating the association between BMI and cervical cancer may be 240 attributed to numerous factors including patient selection criteria, sample size and generalizability 241 of the study population. Among these factors, patient selection criteria may be especially 242 important, because tumor histology seems to be closely associated with BMI37. 243

244 The strengths of this study include the use of careful clinical staging, histopathology, and reliable phylogenetic and statistical analysis to assess bacterial community compositional changes 245 using both microbial divergence and taxon-based methods. Additionally, we followed a complete 246 247 protocol for 16S analysis ranging from the sample collection method, DNA extraction, and microbiome sequencing, thus limiting artifactual variations. Although this study has yielded 248 249 intriguing findings, an important limitation is the small sample size. Consequently, the sample size 250 limited our ability to weigh statistical power. Yet despite the relatively small size of this 251 prospective study, large statistically significant differences were still observed, and we believe the results presented herein provide solid evidence elucidating the role of the gut microbiome as it 252 pertains to the treatment of cervical cancer. We hope the integration of these data will produce 253

actionable strategies geared toward targeting and manipulating the microbiome in order toultimately improve cervical cancer therapy.

In conclusion, our study demonstrates that the diversity of gut microbiota is associated with 256 a favorable response to chemoradiation. Additionally, compositional variation among patients 257 correlated with short term and long-term survival. Our study demonstrates that gut diversity is a 258 259 significant factor for predicting OS in CC patients undergoing CRT when BMI is accounted for, and may help explain the "obesity paradox" in cancer response. Moreover, analysis of immune 260 cells from cervical tumor brush samples by flow cytometry revealed that an association between 261 high microbial diversity, increased tumor infiltration of CD4+ lymphocytes and the activation of 262 CD4 cells over the course of radiation therapy. The correlation between gut diversity and increased 263 tumor infiltration of CD4+ lymphocytes suggest that patients harboring a more diverse gut 264 microbiota at baseline may benefit from CRT to a greater extent. The significance of our study lies 265 in that modulation of gut microbiota before chemoradiation might provide an alternative way to 266 267 enhance treatment efficacy and improve treatment outcomes in cervical cancer patients. Additional studies exploring the relationship between gut diversity, chemoradiation, and treatment efficacy 268 are needed to further understand the role of the gut microbiome in cervical cancer treatment. 269

270

#### 271 METHODS

Participants and clinical data. Gut microbiome and cervical swab samples were collected
prospectively from cervical cancer patients according to a protocol approved by The University of
Texas MD Anderson Cancer Center Institutional Review Board (MDACC 2014-0543) for patients
with biopsy-proven carcinoma of the cervix treated at MD Anderson and the Lyndon B. Johnson
Hospital Oncology Clinic from September 22, 2015, to January 11, 2019. All patients had new

diagnoses of locally advanced, nonmetastatic carcinoma of the cervix and underwent definitive
CRT with EBRT followed by brachytherapy. Patients received a minimum of 45 Gy via EBRT in
25 fractions over 5 weeks with weekly cisplatin followed by two brachytherapy sessions at
approximately weeks 5 and 7 with EBRT in between for gross nodal disease or persistent disease
in the parametrium. Patients with stage IB1 cancer were given CRT due to the presence of nodal
disease. Clinical variables, demographics, and pathologic reports were abstracted from electronic
medical records.

284

Sample collection and DNA extraction. Stool was collected from all patients by a clinician performing rectal exams at five time points (baseline; weeks 1, 3, and 5 of radiotherapy; and 3 months after CRT completion) using a matrix-designed quick-release Isohelix swab to characterize the diversity and composition of the microbiome over time. The swabs were stored in 20  $\mu$ l of protease K and 400  $\mu$ l of lysis buffer (Isohelix) and kept at -80°C within 1 h of sample collection.

16S rRNA gene sequencing and sequence data processing. 16S rRNA sequencing was 291 performed for fecal samples obtained from all patients at four time points to characterize the 292 293 diversity and composition of the microbiome over time. 16S rRNA gene sequencing was done at the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine. 294 295 16S rRNA was sequenced using approaches adapted from those used for the Human Microbiome 296 Project<sub>41</sub>. The 16S rDNA V4 region was amplified via polymerase chain reaction with primers that 297 contained sequencing adapters and single-end barcodes, allowing for pooling and direct 298 sequencing of polymerase chain reaction products. Amplicons were sequenced on the MiSeq 299 platform (Illumina) using the 2 x 250-bp paired-end protocol, yielding paired-end reads that

overlapped nearly completely. Sequence reads were demultiplexed, quality-filtered, and 300 subsequently merged using the USEARCH sequence analysis tool (version 7.0.1090) (4). 16S 301 302 rRNA gene sequences were bundled into operational taxonomic units at a similarity cutoff value of 97% using the UPARSE algorithm<sup>42</sup>. To generate taxonomies, operational taxonomic units were 303 mapped to an enhanced version of the SILVA rRNA database containing the 16Sv4 region. A 304 305 custom script was used to create an operational taxonomic unit table from the output files generated as described above for downstream analyses of  $\alpha$ -diversity,  $\beta$ -diversity, and phylogenetic trends. 306 Principal coordinates analysis was performed by institution and sample set to make certain no 307 batch effects were present. 308

309

Flow Cytometry. Immunostaining was performed according to standard protocols43. Cells were 310 fixed using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, Waltham, MA) and 311 stained with a 16 color panel with antibodies from Biolegend (San Diego, CA), BD Bioscience 312 313 (San Jose, CA), eBioscience (Waltham, MA), and Life Technologies (Carlsbad, CA). Analysis was performed on a 5-laser, 18 color LSRFortessa X-20 Flow Cytometer (BD Biosciences, San 314 315 Jose, CA). Analysis was performed using FlowJo version 10 (Flowjo LLC, Ashland, OR). We 316 then followed a similar previously published method<sub>43</sub>. Briefly, the cells were incubated with the antibodies for surface markers at 4°C in dark for 30 minutes. They were then washed twice with 317 318 FACS buffer and fixed and permeabilized with FOXP3 Fix/perm Kit (ThermoFisher Scientific, 319 Waltham, MA). Next, intracellular staining was performed by preparing the antibodies in 320 permeabilization buffer and incubating the cells for 30 minutes at 4°C in the dark. Cells were 321 washed with FACS buffer twice and prepared for acquisition on an LSR Fortessa X-20 analyzer 322 at the Flow Cytometry Core at MD Anderson Cancer Center and were analyzed using FlowJo software (FlowJo, LLC, Ashland, OR). Compensation controls were prepared using OneComp
ebeads (eBioscience, Waltham, MA) and fluorescence minus one controls were used<sub>43</sub>.

325

Statistical analyses. For microbiome analysis, rarefaction depth was set at 7066 reads. The 326 Shannon diversity index (SDI) was used to evaluate  $\alpha$ -diversity (within samples), and principle 327 328 coordinates analysis of unweighted UniFrac distances was used to examine β-diversity (between samples). Patient and tumor characteristics were analyzed by univariate and multivariate Cox 329 regression models for Recurrence-free survival (RFS) and Overall survival (OS) based on 330 univariate p-value < 0.1. Characteristics included age, body mass index (BMI), race, FIGO stage, 331 grade, histology, nodal status, smoking status, antibiotic use and max tumor size. For each outcome 332 of interest, a multivariate Cox regression analysis was performed to adjust for the effects of 333 prognostic factors identified on univariate analysis as influencing survival in cervical cancer. 334 These analyses were conducted using covariates with  $p \le 0.1$  in a stepwise fashion. We also ran a 335 336 correlation analysis of alpha diversity metrics with tumor flow cytometry markers using a linear regression and Spearman's correlation. Alpha (within sample) diversity was evaluated using SDI. 337 The relative abundance of microbial taxa, classes, and genera present in long term vs short term 338 339 survivors was determined using LDA Effect Size44, applying the one-against-all strategy with a threshold of 3.5 for the logarithmic LDA score for discriminative features and  $\alpha$  of 0.05 for 340 341 factorial Kruskal-Wallis testing among classes. Long term survivors were classified as patients 342 who had a follow up of two years or more and were alive at time of last follow up, while short 343 term survivors had a follow up of one year or less. LDA Effect Size analysis was restricted to bacteria present in 20% or more of the study population. Kaplan-Meier curves were generated for 344 patients with normal BMI and overweight/obese BMI based on Cox analysis and clostridia 345

abundance. The significance of differences was determined using the log-rank test. Statistical
significance was set at an alpha of 5% for a two-sided p-value. Analyses were conducted using
Rstudio version Orange Blossom – 1.2.5033.

349

#### 350 ACKNOWLEDGEMENTS

- 351 This research was supported in part by the Radiological Society of North America Resident/Fellow
- 352 Award (to L.E.C.), the National Institutes of Health (NIH) through MD Anderson's Cancer Center
- 353 Support Grant P30CA016672, the Emerson Collective and the National Institutes of Health T32
- grant #5T32 CA101642-14 (T.T.S). This study was partially funded by The University of Texas
- 355 MD Anderson Cancer Center HPV-related Cancers Moonshot (L.E.C and A.K.). The human
- subjects who participated in this study are gratefully acknowledged.

#### 357 AUTHOR CONTRIBUTION

All authors were involved in subject identification, data collection, interpretation of the statistical analysis, and review and approval of the final manuscript. The study concept was conceived by L.E.C., A.K., M.B.E.A, and T.T.S. The manuscript was written by T.T.S.

#### **361 COMPETING INTERESTS**

362 The authors report no conflicts of interest, financial or otherwise, related to the subject of this363 article.

#### **364 ROLE OF FUNDING SOURCES**

- 365 The funding sources were not involved in the research hypothesis development, study design,
- data analysis, or manuscript writing. Data access was limited to the authors of this manuscript.

367	The investigation described in this manuscript was presented in-part by Dr. Travis T. Sims
368	during the American Society Of Clinical Oncology (ASCO) 2020 Annual Meeting, May 29-June
369	2, 2020.
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	
383	
384	
385	
386	
387	
388	
389	

#### **390 REFERENCES**

- 1. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age,
- race/ethnicity, histological subtype, and stage at diagnosis in the United States. *Prev Med.*

393 2019;123:316-323. doi:10.1016/j.ypmed.2019.04.010

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7-34.
   doi:10.3322/caac.21551
- 396 3. Monk BJ, Tewari KS, Koh W-J. Multimodality Therapy for Locally Advanced Cervical
- 397 Carcinoma: State of the Art and Future Directions. *J Clin Oncol.* 2007;25(20):2952-2965.
- 398 doi:10.1200/JCO.2007.10.8324
- 4. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy
  human microbiome. *Nature*. 2012;486(7402):207-214. doi:10.1038/nature11234
- 401 5. Cho JA, Chinnapen DJF. Targeting friend and foe: Emerging therapeutics in the age of gut
- 402 microbiome and disease. *J Microbiol*. 2018;56(3):183-188. doi:10.1007/s12275-018-8037-z
- 403 6. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome,
  404 cancer, and cancer therapy. *Nat Med.* 2019;25(3):377-388. doi:10.1038/s41591-019-0377-7
- 405 7. Jin Y, Dong H, Xia L, et al. The Diversity of Gut Microbiome is Associated With Favorable
- 406 Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. J
- 407 Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(8):1378-1389.
- 408 doi:10.1016/j.jtho.2019.04.007
- 409 8. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota:
- 410 friends or foes? *Nat Rev Immunol*. 2010;10(10):735-744. doi:10.1038/nri2850

411	9.	McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve
412		therapeutic response in cancer. Lancet Oncol. 2019;20(2):e77-e91. doi:10.1016/S1470-
413		2045(18)30952-5
414	10	Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer.
415		2017;17(5):271-285. doi:10.1038/nrc.2017.13
416	11.	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-

- 417 PD-1 immunotherapy in melanoma patients. *Science*. 2018;359(6371):97-103.
- 418 doi:10.1126/science.aan4236
- 419 12. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but Not Single-Dose
- 420 Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-
- 421 CTLA-4 Antibody. *Clin Cancer Res.* 2009;15(17):5379-5388. doi:10.1158/1078-0432.CCR422 09-0265
- 423 13. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local Radiation
- 424 Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific
- 425 Effector Cells That Traffic to the Tumor. *J Immunol*. 2005;174(12):7516-7523.
- 426 doi:10.4049/jimmunol.174.12.7516
- 427 14. Lhuillier C, Rudqvist N-P, Elemento O, Formenti SC, Demaria S. Radiation therapy and
- 428 anti-tumor immunity: exposing immunogenic mutations to the immune system. *Genome*
- 429 *Med.* 2019;11(1):40. doi:10.1186/s13073-019-0653-7
- 430 15. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor
- 431 require CD8+ T cells: changing strategies for cancer treatment. *Blood*. 2009;114(3):589-595.
- 432 doi:10.1182/blood-2009-02-206870

433	16.	Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using
434		immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313-322.
435		doi:10.1038/nrc.2018.6
436	17.	Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS. Assessing the interactions
437		between radiotherapy and antitumour immunity. Nat Rev Clin Oncol. 2019;16(12):729-745.
438		doi:10.1038/s41571-019-0238-9
439	18.	Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor
440		immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-1089.
441		doi:10.1126/science.aac4255
442	19.	Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the
443		immune system. Science. 2012;336(6086):1268-1273. doi:10.1126/science.1223490
444	20.	Meir H van, Nout RA, Welters MJP, et al. Impact of (chemo)radiotherapy on immune cell
445		composition and function in cervical cancer patients. OncoImmunology.
446		2017;6(2):e1267095. doi:10.1080/2162402X.2016.1267095
447	21.	Jordanova ES, Gorter A, Ayachi O, et al. Human leukocyte antigen class I, MHC class I
448		chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines
449		survival of cervical cancer patients? Clin Cancer Res Off J Am Assoc Cancer Res.
450		2008;14(7):2028-2035. doi:10.1158/1078-0432.CCR-07-4554
451	22.	Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota
452		modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol.
453		2017;14(6):356-365. doi:10.1038/nrgastro.2017.20

454	23. Kohl KD, Weiss RB, Cox J, Dale C, Denise Dearing M. Gut microbes of mammalian
455	herbivores facilitate intake of plant toxins. van Dam N, ed. Ecol Lett. 2014;17(10):1238-
456	1246. doi:10.1111/ele.12329
457	24. Muls A, Andreyev J, Lalondrelle S, Taylor A, Norton C, Hart A. Systematic Review: The
458	Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women With a
459	Gynecological Malignancy. Int J Gynecol Cancer. 2017;27(7):1550-1559.
460	doi:10.1097/IGC.000000000000999
461	25. Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory
462	dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. Gut.
463	2018;67(1):97-107. doi:10.1136/gutjnl-2017-313789
464	26. Sokol H, Adolph TE. The microbiota: an underestimated actor in radiation-induced lesions?
465	Gut. 2018;67(1):1-2. doi:10.1136/gutjnl-2017-314279
466	27. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic
467	systolic heart failure: the obesity paradox. Am J Cardiol. 2003;91(7):891-894.
468	doi:10.1016/s0002-9149(03)00031-6
469	28. Lavie CJ, De Schutter A, Milani RV. Healthy obese versus unhealthy lean: the obesity
470	paradox. Nat Rev Endocrinol. 2015;11(1):55-62. doi:10.1038/nrendo.2014.165
471	29. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy Compared With Laparotomy for
472	Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study
473	LAP2. J Clin Oncol. 2009;27(32):5331-5336. doi:10.1200/JCO.2009.22.3248
474	30. S A-A, A S, J K. Obesity and cancer. J Med. 2002;33(1-4):73-86.

475	31.	Chen H-N, Chen X-Z, Zhang W-H, et al. The Impact of Body Mass Index on the Surgical
476		Outcomes of Patients With Gastric Cancer: A 10-Year, Single-Institution Cohort Study.
477		Medicine (Baltimore). 2015;94(42):e1769. doi:10.1097/MD.000000000001769
478	32.	Gunderson CC, Java J, Moore KN, Walker JL. The impact of obesity on surgical staging,
479		complications, and survival with uterine cancer: A Gynecologic Oncology Group LAP2
480		ancillary data study. Gynecol Oncol. 2014;133(1):23-27. doi:10.1016/j.ygyno.2014.01.041
481	33.	Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk: a meta-
482		analysis. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2016;25(3):232-238.
483		doi:10.1097/CEJ.00000000000164
484	34.	Chi DS, Berchuck A, Dizon DS, Yashar CM. Principles and Practice of Gynecologic
485		Oncology. Seventh edition. Wolters Kluwer; 2017.
486	35.	Nagaraju GP, Rajitha B, Aliya S, et al. The role of adiponectin in obesity-associated female-
487		specific carcinogenesis. Cytokine Growth Factor Rev. 2016;31:37-48.
488		doi:10.1016/j.cytogfr.2016.03.014
489	36.	Martín-López R, Hernández-Barrera V, De Andres AL, Garrido PC, De Miguel AG, García
490		RJ. Breast and cervical cancer screening in Spain and predictors of adherence. Eur J Cancer
491		Prev. 2010;19(3):239–245. doi:10.1097/CEJ.0b013e3283372125
492	37.	Lacey JV, Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for
493		adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer.
494		2003;98(4):814-821. doi:10.1002/cncr.11567

495	38. Brinton LA, Herrero R, Reeves WC, de Britton RC, Gaitan E, Tenorio F. Risk Factors for
496	Cervical Cancer by Histology. Gynecol Oncol. 1993;51(3):301-306.
497	doi:10.1006/gyno.1993.1294
498	39. Törnberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast
499	and female genital tract in 47,000 women followed for 25 years. Br J Cancer.
500	1994;69(2):358-361. doi:10.1038/bjc.1994.65
501	40. Lane G. Obesity and gynaecological cancer. <i>Menopause Int.</i> 2008;14(1):33-37.
502	doi:10.1258/mi.2007.007036
503	41. The Human Microbiome Project Consortium. A framework for human microbiome research.
504	Nature. 2012;486(7402):215-221. doi:10.1038/nature11209
505	42. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat
506	Methods. 2013;10(10):996-998. doi:10.1038/nmeth.2604
507	43. Dorta-Estremera S, Colbert LE, Nookala SS, et al. Kinetics of Intratumoral Immune Cell
508	Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys.
509	2018;102(3):593-600. doi:10.1016/j.ijrobp.2018.06.404
510	44. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation.
511	Genome Biol. 2011;12(6):R60. doi:10.1186/gb-2011-12-6-r60

#### 513 Figures











#### 522 Fig. 2. Compositional differences of the gut microbiome in short and long term survivors.

(A) The different abundance of bacterial genus between the two groups were identified by 523 LEfSe. It was significantly different when alpha value of the factorial Kruskal–Wallis test was 524 <0.05 and the logarithmic LDA score was >3.0. The left histogram showed the LDA scores of 525 genera differentially abundant between the two groups. The taxonomy was listed, followed by its 526 core group. Putative species (Specific OTUs) identified as significantly more enriched/depleted 527 (Fisher/Wilcoxon test p value < 0.05) in patients with short-term vs long-term in baseline 528 samples. (B) Cladogram representation of the significantly different taxa features from phylum 529 (inner circle) to genus (outer circle) (C) The right heatmap showed the relative abundance of 530 specific bacteria by phylum, class, order, family and genus between short-term and long-term 531 532 survivors.



534 Fig 3. Correlation analysis of Shannon Diversity Index with tumor immune signatures.

535 (A,B,C,D) Spearman correlations between Shannon Diversity Index and CD4+, CD4+ Ki67+,

536 CD4+ CD69+, and CD4+ PD1+. Statistical analysis was performed by Spearman correlation or

537 Mann-Whitney tests.



539 Supplemental Fig 1. The fecal microbiota of individuals with cervical cancer.

The fecal microbiota of individuals with cervical cancer by demographics. Diversity (within
sample diversity) was measured using the Shannon diversity metric and Beta diversity (between
sample diversity) was determined by unweighted Unifrac. No differences were observed in either
metric by cancer histology (A,D), grade (B,E) or cancer stage (C,F).



545 Supplemental Fig 2. Relationship between gut diversity and BMI.

546 Kaplan-Meier curves for (A) recurrence free survival, (B) overall survival stratified by relative

547 abundance of *Pasteurellales*. Kaplan-Meier curves for (C) recurrence free survival, (D) overall

- 548 survival stratified by relative abundance of *Haemophilus*. Kaplan-Meier curves for (E)
- 549 recurrence free survival, (F) overall survival stratified by relative abundance of *Veillonella*.
- 550 Cases represent patients.

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	0.93 (0.87-0.98)	0.0096	0.93* (0.88-0.99)	0.03‡
BMI (kg/m2)	0.92 (0.84-1)	0.096	0.87* (0.77-0.98)	0.02‡
Normal (18.5 to 24.9)	1 (reference)			
Overweight (25 to 29.9)	0.81(0.26-2.53)	0.715		
Obese (30 or more)	0.47(0.13-1.67)	0.240		
Race/Ethnicity				
Asian	1 (reference)			—
Black	0.37(0.02-5.90)	0.479		_
Hispanic	0.39 (0.05-3.21)	0.382		_
White	0.39 (0.05-3.31)	0.390		
Other	4.1309E-08(-inf - +inf)	0.998		
Stage				
Ι	1 (reference)			—
II	1.50 (0.31-7.34)	0.615		_
III	3.99 (0.80-20.01)	0.091		
IV	2.54 (0.23-28.12)	0.447		—
Grade				
Well	1 (reference)			
Moderate	55297546(-inf - +inf)	0.998		
Poor	97336741.9(-inf - +inf)	0.998		
Unknown	76285161.4(-inf - +inf)	0.998		—
Histology				
Squamous	1 (reference)			
Adenocarcinoma/Adenosquamous	1.06(0.34-3.34)	0.918		
Node Level on PET				
Common Iliac	1 (reference)			
External Iliac	1.33 (0.35-4.95)	0.675		
Internal Iliac	0.67 (0.07-6.89)	0.736	_	

551 Table 1. Univariate and multivariate Cox regression analysis for recurrence-free survival

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
Para-Aortic	1.31 (0.14-12.55)	0.818		
None	0.34 (0.06-2.09)	0.245		
Max Tumor Dimension on MRI	1.3 (1-1.8)	0.042		
Smoking status				
Current	1 (reference)			
Former	0.91 (0.10-7.84)	0.934		
Never	0.89(0.11-7.17)	0.909		
Antibiotic Use				
No	1 (reference)			
Yes	78371200.7 (-inf - +inf)	0.998		_
Brachytherapy				
HDR	1 (reference)			
PDR	1.41 (0.48-4.149)	0.532		_
Baseline Gut Alpha Diversity				
Observed OTU	0.99 (0.97-1)	0.21		_
Shannon	0.51 (0.23-1.1)	0.087	0.36* (0.15-0.84)	0.018‡
Simpson	0.025 (0.000036-1.7)	0.087		_
Inverse Simpson	0.93 (0.84-1)	0.11		_
Fisher	0.95 (0.88-1)	0.23		
Camargo	13 (0.14-1300)	0.27		_
Pielou	0.02 (0.00026-1.6)	0.081		

553 *CI*, Confidence interval; *HR*, hazard ratio. \*Significant hazard ratios. ‡Significant *P* value.

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	0.95 (0.87-1)	0.23	_	_
BMI (kg/m2)	0.83 (0.69-1)	0.055	0.78* (0.623-0.97)	0.025‡
Normal (18.5 to 24.9)	1 (reference)		—	
Overweight (25 to 29.9)	0.23(0.08-2.32)	0.323	_	
Obese (30 or more)	0.42 (0.06-4.56)	0.19	_	_
Race/Ethnicity				
Asian	1 (reference)		_	
Black	4.46E-09 (-inf - +inf)	0.999	_	
Hispanic	0.23(0.02-2.22)	0.204	_	_
White	0.17 (0.02-1.90)	0.151	—	
Other	4.48E-09 (-inf - +inf)	0.999	_	
Stage				
Ι	1 (reference)		_	
II	1.19 (0.12-11.43)	0.881	—	
III	1.49 (0.09-23.93)	0.776	—	
IV	5.13 (0.32-82.34)	0.248	_	
Grade				
Well	1 (reference)		—	
Moderate	116103697.1 (-inf - +inf)	0.999	—	
Poor	46065187.92(-inf - +inf)	0.999	—	
Unknown	149251105.9(-inf - +inf)	0.999	_	
Histology				
Squamous	1 (reference)		_	
Adenocarcinoma/Adenosquamous	3.40 (0.69-16.90)	0.134	_	
Node Level on PET				
Common Iliac	1 (reference)		_	
External Iliac	1.099 (0.09-12.86)	0.306	—	
Internal Iliac	4.83 (0.24-98.040)	0.999	_	
Para-Aortic	5.9333E-08 (-inf - +inf)	0.354		

556 Table 2. Univariate and multivariate Cox regression analysis for overall survival

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
None	3.34(0.26-42.69)	0.940	_	
Max Tumor Dimension on MRI	1.2 (0.77-1.8)	1.2		_
Smoking status				
Current	1 (reference)			_
Former	106318829.2 (-inf - +inf)	0.999		_
Never	61091037.65 (-inf - +inf)	0.999		_
Antibiotic Use				
No	1 (reference)			_
Yes	0.53 (0.06-4.56)	0.564		_
Brachytherapy				
HDR	1 (reference)			_
PDR	0.89 (-1.61-1.39)	0.884		_
Baseline Gut Alpha Diversity				
Observed OTU	0.98 (0.95-1)	0.14		
Shannon	0.34 (0.1-1.1)	0.08	0.19* (0.043-0.83)	0.028‡
Simpson	0.0059 (1.2e-05-2.9)	0.1		_
Inverse Simpson	0.85 (0.7-1)	0.13		_
Fisher	0.91 (0.79-1)	0.15		_
Camargo	2200 (0.84-5800000)	0.055		_
Pielou	0.0036 (5e-06-2.5)	0.093		

559

*CI*, Confidence interval; *HR*, hazard ratio. \*Significant hazard ratios. ‡Significant *P* value.

- 561 Table 3. Correlation of baseline gut diversity (Inverse Shannon Diversity) with phenotype of tumor
- 562 infiltrating lymphocytes during chemoradiation treatment. The percent of live lymphocytes
- 563 expressing each marker was correlated with baseline Shannon diversity of the gut microbiome.

	P-value*	Q value	<b>R</b> <sub>2</sub>
CD4+Ki.67+ at T4	0.004‡	0.0714	<u> </u>
CD4+CD69+ at T3	0.004‡	0.1429	
CD4+PD1+ at T3	0.0367‡	0.2143	
CD4+CTLA4+ at T3	0.057	0.2857	
CD4+			0.1

564 \*P-value correlation of immune metric with baseline gut diversity

565 ‡Significant *P* value.

## 566 Supplemental Table 1. Patient and tumor characteristics (N=55)

	Ν	(%)
Median age, yrs (range)	48 (28-72)	
BMI, Mean (SD), kg/m2	28.7(6.06)	
Race/Ethnicity		
Asian	2	(36.4)
Black	4	(18.2)
Hispanic	24	(43.6)
White	24	(43.6)
Other	1	(1.8)
FIGO Stage		
IA1	1	(1.8)
IA2	0	(0)
IB1	5	(9.09)
IB2	6	(10.9)
IIA	3	(5.45)
IIB	28	(50.9)
IIIA	9	(16.3)
IIIB	0	(0)
IVA	3	(5.45)
IVB	0	(0)
Grade		
Well	4	(7.2)
Moderate	20	(36.3)
Poor	25	(45.4)
Unknown	6	(10.9)
Histology		
Squamous	43	(78.1)
Adenocarcinoma	8	(18.1)
Adenosquamous	3	(3.63)
Node Level on PET		
Common Iliac	9	(16.3)

External Iliac	23	(41.8)
Internal Iliac	5	(9.09)
Para-Aortic	3	(5.45)
None	15	(27.2)
Median cervical tumor size (cm)	5.4	—
Smoking status		
Current	4	(7.27)
Former	20	(36.3)
Never	31	(56.3)
Antibiotic Use		
No	5	(9.1)
Yes	50	(90.9)
Brachytherapy		
HDR	21	(38.2)
PDR	34	(61.8)
Concurrent Chemotherapy (cycles)		
Cisplatin		
(1-3)	2	(3.6)
(≥4)	51	(92.7)
Carboplatin		
(2)	1	(1.8)
Carboplatin + Cisplatin		
(2)+(2)	1	(1.8)

568	FIGO- International	Federation	of Gyr	necology a	nd Obstetrics
-----	---------------------	------------	--------	------------	---------------

570 HDR-High Dose Rate PDR- Pulsed Dose Rate

# 571 Supplemental Table 2. Univariate Cox regression analysis for recurrence-free survival – Alpha Diversity all

# 572 time points

Characteristics	Univariate model		
	HR (95% CI)	P value	
Observed OTU			
Baseline	0.99 (0.97-1)	0.21	
Week 1	1 (0.97-1)	0.69	
Week 3	0.99 (0.96-1)	0.59	
Week 5	1 (0.98-1)	0.71	
Week 12	1 (0.98-1)	0.77	
Shannon			
Baseline	0.51 (0.23-1.1)	0.087	
Week 1	0.94 (0.2-4.4)	0.94	
Week 3	1.2 (0.25-5.6)	0.83	
Week 5	0.83 (0.35-1.9)	0.66	
Week 12	2.7 (0.13-57)	0.51	
Simpson			
Baseline	0.025 (0.00036-1.7)	0.087	
Week 1	13 (1.4e-05-1.2e+07)	0.13	
Week 3	52 (6.6e-05-4.1e+07)	0.57	
Week 5	0.31 (0.013-7.8)	0.48	
Week 12	130000 (7.5e-13-2.2e+22)	0.56	

Characteristics	Univariate model	
	HR (95% CI)	P value
Inverse Simpson		
Baseline	0.93 (0.84-1)	0.11
Week 1	0.96 (0.79-1.2)	0.69
Week 3	1 (0.95-1.1)	0.34
Week 5	1 (0.92-1.2)	0.54
Week 12	1.1 (0.81-1.4)	0.59
Fisher		
Baseline	0.95 (0.88-1)	0.23
Week 1	0.97 (0.86-1.1)	0.66
Week 3	0.96 (0.83-1.1)	0.6
Week 5	1 (0.91-1.2)	0.69
Week 12	1 (0.89-1.2)	0.81

*CI*, Confidence interval; *HR*, hazard ratio.

\*Significant hazard ratios.

576 ‡Significant *P* value.

# Supplemental Table 3. Univariate Cox regression analysis for overall survival – Alpha Diversity all time points

Characteristics	Univariate model		
	HR (95% CI)	P value	
Observed OTU			
Baseline	0.98 (0.95-1)	0.14	
Week 1	0.98 (0.94-1)	0.35	
Week 3	0.97 (0.92-1)	0.21	
Week 5	1 (0.96-1)	0.98	
Week 12	NA (NA-NA)	1	
Shannon			
Baseline	0.34 (0.1-1.1)	0.08	
Week 1	0.48 (0.063-3.7)	0.48	
Week 3	1.2 (0.25-5.6)	0.83	
Week 5	0.23 (0.037-1.4)	0.11	
Week 12	NA (NA-NA)	1	
Simpson			
Baseline	0.0059 (1.2e-05-2.9)	0.1	
Week 1	0.45 (1.1e-08-1.8e+07)	0.93	
Week 3	0.009 (1.7e-07-490)	0.4	
Week 5	1.4 (0.00063-3200)	0.93	
Week 12	NA (NA-NA)	1	

Characteristics	Univariate model	
	HR (95% CI)	P value
Inverse Simpson		
Baseline	0.85 (0.7-1)	0.13
Week 1	0.86 (0.62-1.2)	0.39
Week 3	0.81 (0.61-1.1)	0.15
Week 5	0.89 (0.66-1.2)	0.46
Week 12	NA (NA-NA)	1
Fisher		
Baseline	0.91 (0.79-1)	0.15
Week 1	0.91 (0.74-1.1)	0.34
Week 3	0.84 (0.64-1.1)	0.22
Week 5	0.99 (0.79-1.3)	0.94
Week 12	NA (NA-NA)	1

- *CI*, Confidence interval; *HR*, hazard ratio.
- \*Significant hazard ratios.
- 582 ‡Significant *P* value.